Efter gentagen intravenøs administration af en 300 mg dosis natalizumab til MS- patienter var den observerede middelværdi for den maksimale serumkoncentration 110 ± 52 μg/ ml.
Following the repeat intravenous administration of a 300 mg dose of natalizumab to MS patients, the mean maximum observed serum concentration was 110 ± 52 μ g/ ml.